metformin has been researched along with miglitol in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (10.00) | 18.2507 |
| 2000's | 8 (40.00) | 29.6817 |
| 2010's | 10 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Lardinois, CK | 1 |
| Riddle, MC | 1 |
| Hanefeld, M; Naditch, L; Raptis, SA; Rybka, J; Schernthaner, G; Standl, E | 1 |
| Chiasson, JL; Naditch, L | 1 |
| Maislos, M; Rybka, J; Schernthaner, G; Segal, P; Van Gaal, L | 1 |
| Chawla, S; Takiya, L | 1 |
| Fischer, S; Hanefeld, M | 1 |
| Haslbeck, M; Jakob, S; Kellerer, M; Linn, T | 1 |
| Adelman, MH; Monte, SV; Paladino, JA; Schentag, JJ | 1 |
| Dwivedi, A; Jain, R; Lukram, O | 1 |
| Anno, T; Hashiramoto, M; Hirukawa, H; Kaku, K; Kanda-Kimura, Y; Kawasaki, F; Kimura, T; Matsuki, M; Mune, T; Shimoda, M; Tatsumi, F; Tawaramoto, K | 1 |
| Fukatsu, A; Sakai, S; Samukawa, Y; Sasaki, T; Seino, Y; Ubukata, M | 1 |
| Fukase, H; Harigai, M; Iida, S; Ikeda, S; Kasahara, N; Miyata, K; Ohba, Y; Saito, T; Takano, Y; Terao, K | 1 |
| Goto, M; Hariya, N; Mochizuki, K; Osonoi, T; Saito, M | 1 |
| Davis, SN; Hedrington, MS | 1 |
6 review(s) available for metformin and miglitol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Type 2 diabetes: glycemic targets and oral therapies for older patients.
Topics: 1-Deoxynojirimycin; Acarbose; Age Factors; Aged; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Glucosamine; Humans; Hypoglycemic Agents; Imino Pyranoses; Metformin; Piperidines; Sulfonylurea Compounds; Trisaccharides | 1998 |
Oral pharmacologic management of type 2 diabetes.
Topics: 1-Deoxynojirimycin; Acarbose; Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Metformin; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; United States | 1999 |
Therapeutic options for the management of type 2 diabetes mellitus.
Topics: 1-Deoxynojirimycin; Adult; Diabetes Mellitus, Type 2; Disease Management; Education, Medical, Continuing; Education, Pharmacy, Continuing; Glucosamine; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Insulin Aspart; Managed Care Programs; Metformin; Thiazoles; Thiazolidinediones; United States | 2002 |
[Continuation 50. Type 2 diabetes: possibilities and limitations of pharmacological therapy].
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Blood Glucose; Carbamates; Contraindications; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Fasting; Follow-Up Studies; Germany; Glucosamine; Glyburide; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Imino Pyranoses; Insulin; Metformin; Middle Aged; Nateglinide; Obesity; Patient Compliance; Phenylalanine; Pioglitazone; Piperidines; Practice Guidelines as Topic; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors | 2003 |
Considerations when using alpha-glucosidase inhibitors in the treatment of type 2 diabetes.
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Inositol; Metformin; Prediabetic State | 2019 |
7 trial(s) available for metformin and miglitol
| Article | Year |
|---|---|
Improved glycaemic control with miglitol in inadequately-controlled type 2 diabetics.
Topics: 1-Deoxynojirimycin; Analysis of Variance; Blood Glucose; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Diabetic; Double-Blind Method; Drug Therapy, Combination; Female; Glucosamine; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Imino Pyranoses; Male; Metformin; Middle Aged; Placebos | 2001 |
The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes.
Topics: 1-Deoxynojirimycin; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Fasting; Female; Glucosamine; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Male; Metformin; Middle Aged; Placebos; Postprandial Period; Racial Groups | 2001 |
Miglitol combined with metformin improves glycaemic control in type 2 diabetes.
Topics: 1-Deoxynojirimycin; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Glucosamine; Humans; Hypoglycemic Agents; Imino Pyranoses; Male; Metformin; Middle Aged; Single-Blind Method | 2001 |
Concomitant use of miglitol and mitiglinide as initial combination therapy in type 2 diabetes mellitus.
Topics: 1-Deoxynojirimycin; Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Fasting; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Isoindoles; Male; Metformin; Middle Aged; Prognosis | 2013 |
Absence of Drug-Drug Interactions Between Luseogliflozin, a Sodium-Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males.
Topics: 1-Deoxynojirimycin; Adult; Antihypertensive Agents; Area Under Curve; Cross-Over Studies; Female; Humans; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Sorbitol; Sulfonylurea Compounds; Thiazolidinediones; Triazoles | 2015 |
A Pharmacokinetic/Pharmacodynamic Drug-Drug Interaction Study of Tofogliflozin (a New SGLT2 Inhibitor) and Selected Anti-Type 2 Diabetes Mellitus Drugs.
Topics: 1-Deoxynojirimycin; Adult; Benzhydryl Compounds; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Interactions; Glucose; Glucosides; Healthy Volunteers; Humans; Hypoglycemic Agents; Inositol; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Pioglitazone; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiazolidinediones; Urine; Young Adult | 2016 |
Add-on therapy with anagliptin in Japanese patients with type-2 diabetes mellitus treated with metformin and miglitol can maintain higher concentrations of biologically active GLP-1/total GIP and a lower concentration of leptin.
Topics: 1-Deoxynojirimycin; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Leptin; Male; Metformin; Middle Aged; Pyrimidines; Treatment Outcome | 2016 |
7 other study(ies) available for metformin and miglitol
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
[Therapy decision based on the glucose triad. Drug treatment of type 2 diabetes].
Topics: 1-Deoxynojirimycin; Acarbose; Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Glucosamine; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Insulin Resistance; Insulin Secretion; Metformin; Obesity; Pioglitazone; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Time Factors | 2003 |
Glucose supply and insulin demand dynamics of antidiabetic agents.
Topics: 1-Deoxynojirimycin; Acarbose; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dietary Carbohydrates; Energy Intake; Follow-Up Studies; Gluconeogenesis; Glucose; Glycated Hemoglobin; Heart Diseases; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Intestinal Absorption; Liver; Metformin; Myocardial Infarction; Thiazolidinediones | 2010 |
Ultra-performance liquid chromatography electrospray ionization-tandem mass spectrometry method for the estimation of miglitol in human plasma using metformin as the internal standard.
Topics: 1-Deoxynojirimycin; Chromatography, High Pressure Liquid; Humans; Metformin; Reference Standards; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Statistics as Topic | 2011 |